Navigation Links
Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
Date:9/6/2007

KNOXVILLE, TN--Provectus Pharmaceuticals, Inc. (OTCBB:PVCT) announced that it has obtained approval to begin Phase 2 clinical testing of Provecta for the treatment of Stage III and IV metastatic melanoma, the most aggressive and deadly form of skin cancer. The multi-center study is designed to evaluate efficacy of Provecta in a total of 80 subjects.

In the study, Provecta will be injected into up to 20 tumors in each subject. Additional treatment with Provecta may be made 8 to 16 weeks after this initial injection, if deemed necessary by the investigator. Response will be observed for 1 year, during which data will be gathered for assessment of objective response rate, progression free survival, quality of life and safety. In addition, CT imaging will be used to monitor changes in any internal (e.g., visceral or brain) metastases. The lead site for the study is the Sydney Melanoma Unit in Australia. Over the next several months the study will expand to include sites in a number of major population centers in Australia as well as several sites in the U.S.

Craig Dees, Ph.D., Chief Executive Officer of Provectus, stated, Building on the results from our Phase 1 study, which looked at safety and objective response upon injection of Provecta into more than 100 metastatic melanoma tumors in 20 subjects, we have put forth an aggressive clinical plan to drive toward approval of the drug for use in this devastating disease. Dees continued, Preliminary analysis of data from Phase 1 shows that Provecta, which has received orphan drug designation in the U.S., was well tolerated with generally mild side effects. Having completed final follow-up for the last of these subjects, we expect to announce summary response data in the near future.


'/>"/>
Contact: Janet Vasquez
janet@investorrelationsgroup.com
212-825-3210
Provectus Pharmaceuticals
Source:Eurekalert

Page: 1

Related medicine news :

1. Risk of heart disease begins in teens
2. Cancer Begins With Epigenetic Changes: Study
3. Learning About Healthy Diet Choices Begins At Schools
4. China Begins Human Trials For HIV/AIDS Drug
5. Administration of Fish Drug for Asthma Patients Begins in Andhra
6. Harvard Begins Controversial Human Stem Cell Cloning Project
7. Writing on the Wall - Lead Poisoning Begins at Home?Paints Could Be Toxic!
8. The Blessing of Good Mental Health Begins with Breast Milk, Says a Study
9. India sounds bird flu alert as migration season begins
10. Keys to Good Health in Old Age Begins in Midlife
11. Cancer Prevention Begins During Pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... 2016 , ... The International Yoga Teacher Training schoo l will ... close to the town famous for its sunsets, Oia. This all inclusive yoga training ... have an amazing experience in Greece, we just can’t stay away” says Co-Founder Carri ...
(Date:5/6/2016)... ... May 06, 2016 , ... Few events in healthcare ... mostly for its cost despite its potential to wipe out a silent killer, ... of a class called direct-acting antivirals (DAAs)—have created fallout in the courts and ...
(Date:5/6/2016)... ... 2016 , ... “ Crossing Over: Affirmations of Faith in the Midst of ... allowed those holding vigil to glimpse into the supernatural as their lives ended. With ... spiritually and practically gain insight into providing care to terminal patients. , “I ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... in the industry’s gold standard KLAS Performance Report, Epic Consulting 2016 ... assessed organizations that specialize in consulting services for electronic health record (EHR) solutions ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... Einstein ... dedicated Twitter feed to cover the latest news and commentary at the 2016 ASCRS/ASOA ... This meeting of the American Society of Cataract and Refractive Surgery and the American ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 3, 2016   BIOTRONIK , a leader ... Food and Drug Administration (FDA) approval of Iperia ... heart failure patients with access to diagnostic magnetic ... remote monitoring with daily automatic transmission and closed ... in response to physiological demands. ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK will ... extending care beyond the implant at the Heart Rhythm ... in San Francisco . ... the highest quality of patient care and satisfaction possible. ... for each and every tomorrow," said Marlou Janssen ...
(Date:5/3/2016)... , May 3, 2016 Pharmaceutical ... $55 million to a woman who says its talc-based ... awarded Gloria Ristesund $5 million in compensatory ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... against the company. In February, the same court awarded ...
Breaking Medicine Technology: